Ivelisse Sanchez

Company: Biointaxis

Job title: Founder & CSO

Seminars:

Early Toxicology Studies for AAV Gene Therapy to Treat Friedreich’s Ataxia 2:00 pm

Findings from preclinical toxicology studies evaluating the safety profile of AAV-based gene therapy for Friedreich’s Ataxia Leveraging preclinical findings to guide dose selection, identify potential safety concerns, and optimize treatment strategies for human patients Explore critical data on potential vector-related toxicities, biodistribution patterns, and long-term effects in relevant animal modelsRead more

day: Day Two Whole